Th e objective of this study was to investigate quality-of-life outcomes in patients with jaw-opening oromandibular dystonia who had received treatment with botulinum neurotoxin injections. Th e Glasgow Benefi t Inventory (GBI) was used as a post-intervention questionnaire to measure patient benefi t. Twenty-fi ve questionnaires were sent to patients. Of the 12 patients who returned the form (48% response rate), the mean scores for the general GBI subscore (p = 0.001), the social support GBI subscore (p = 0.031), and the physical health GBI subscore (p = 0.002) demonstrated statistically signifi cant benefi t from the injections. No scores demonstrated a negative impact. Botulinum neurotoxin injections were demonstrated to benefi t the quality of life in patients suff ering from jawopening oromandibular dystonia. JAW-OPENING DYSTONIA: QUALITY OF LIFE AFTER BOTULINUM TOXIN INJECTIONS Volume 90, Number 2 www.entjournal.com ■ E10
Introduction
Th e dystonias are a group of disorders characterized by muscle contractions that can produce twisting and repetitive movements or abnormal postures. Dystonia is the third most common movement disorder, with Parkinson disease and essential tremor, respectively, being fi rst and second most common. 1 Many of the dystonias involve the head and neck region; these include torticollis, spasmodic dysphonia, blepharospasm, and oromandibular dystonia (OMD). Dystonias have been demonstrated to have a considerable eff ect on health-related quality of life. Quality-of-life surveys have revealed signifi cant diff erences between patients with dystonia and the general population. 2, 3 However, with the exception of spasmodic dysphonia, little has been published in the otolaryngology literature regarding the treatment of any of these disorders.
OMD involves spasms and jaw deviation produced by the muscles of mastication and the facial and tongue muscles. It was fi rst described by Gowers in 1899 as a condition producing tonic and clonic jaw contractions. 4 In 1910, Meige reported spasms of the eyes in addition to pharyngeal, jaw, and tongue contractions. 5 Meige noted that these spasms were provoked by voluntary actions, such as eating or talking, and were lessened by humming, singing, yawning, chewing, or mouth opening, as is characteristic of dystonias. Th e combination of blepharospasm and OMD is referred to as Meige syndrome.
OMDs are rare disorders with unusual, variable features. Early misdiagnosis and treatment are therefore common. Many patients are initially diagnosed with temporomandibular joint disorder because of that disorder's association with overactivity of the masticatory muscles. OMDs can be subdivided into several subtypes. Th ese are: jaw-opening, jaw-closing, jaw-deviation, and mixed OMDs. Each of these may or may not be associated with tongue and facial musculature involvement.
Th erapy for OMD is occasionally improved with oral medications, but the injection of botulinum neurotoxin (BoNT) into the aff ected muscles is generally accepted as the treatment of choice. BoNT injections are targeted into the masseter, temporalis, and medial pterygoid muscles for jaw-closing dystonia, and BoNT is injected into the lateral pterygoid and submental muscles for jaw-opening dystonia.
Jaw-opening dystonia has been found to be more diffi cult to treat than jaw-closing dystonia, having a poorer response to BoNT therapy and a higher rate of associated complications. 6 Little has been written specifi cally about quality of life aft er BoNT injections in patients with jaw-opening dystonia, especially in the otolaryngology literature. [7] [8] [9] [10] In this article, we report the eff ect of BoNT injections on quality of life for patients suff ering with jaw-opening dystonia.
Patients and methods
Th is study was approved by Rush University Medical Center's Institutional Review Board.
Patients. Patients were included if they had jaw-opening OMD and no contraindications to intramuscular injections.
Injections. BoNT injections for jaw-opening OMD were administered transorally into the lateral pterygoid muscles bilaterally, under electromyographic guidance, with initial doses of 40 units per muscle. Th is dose was titrated upward at subsequent injections if there was little or no improvement and side eff ects did not occur. If dose increases did not suffi ce and more improvement was necessary, a midline injection into the submental complex (geniohyoid, digastric and mylohyoid muscles) was given. Th is injection was given approximately 1 cm posterior to the posterior border of the mandibular arch in the midline. Th e initial dosage to this area was 10 units, which was then titrated to eff ect.
Th e Glasgow Benefi t Inventory (GBI), a postintervention questionnaire, is a well-studied and validated measure of patient benefi t developed especially for otolaryngologic interventions. 11 Th e GBI measures the change in health status produced by surgical interventions, where "health status" is the general perception of wellbeing, including total psychological, social, and physical well-being. We adapted this survey to examine the quality-of-life impact for patients receiving BoNT injections for an established diagnosis of jaw-opening OMD (table). Using the GBI questionnaire, patients chose answers on a scale ranging from 1 (much worse) to 5 (much better).
Twenty-fi ve surveys were sent to patients treated for jaw-opening OMD by the authors. Informed consent was obtained for each participant in the study. Age, sex, time interval between onset of dystonic symptoms and diagnosis, duration of treatment, the interval between injections, total GBI score, and GBI subscores (general well-being, social support, and physical sequelae) were statistically summarized. Th e Wilcoxon signed-rank test was used to determine whether the scores were diff erent from zero. Association between the scores and other factors were examined by the Spearman correlation coeffi cient. Th e statistical signifi cance was set at α = 0.05. Th e data collected General score: Sum of scores of the following 10 questions 1. Since you began BoNT injections, do you feel more or less optimistic? 2. Since you began BoNT injections, do you have more or less self-confi dence? 3. Since you began BoNT injections, do you feel better or worse about yourself? 4. Since you began BoNT injections, is it harder or easier to deal with company? 5. Since you began BoNT injections, are you more or less confi dent about job opportunities? 6. Since you began BoNT injections, are you more or less embarrassed when with a group of people? 7. Since you began BoNT injections, are you more or less self-conscious? 8. Since you began BoNT injections, are you more or less inconvenienced by your jaw dystonia? 9. Since you began BoNT injections, are you able to participate more or less in social activities? 10. Since you began BoNT injections, have you been more or less inclined to withdraw from social situations? Support score: Sum of scores of the following 3 questions 1. Since you began BoNT injections, do you feel that you have more or less support from your friends? 2. Since you began BoNT injections, do you feel that you have more or less support from your family? 3. Since you began BoNT injections, are there more or fewer people who really care about you?
Physical: Sum of scores of the following 5 questions 1. Since you began BoNT injections, do you have to take more or less medicine? 2. Since you began BoNT injections, do you have more or less pain? 3. Since you began BoNT injections, do you feel your ability to speak is better or worse? 4. Since you began BoNT injections, is your ability to swallow better or worse? 5. Since you began BoNT injections, is your ability to chew better or worse?
Adapted with permission from Robinson K, Gatehouse S, Browning CG. Measuring patient benefi t from otorhinolaryngological surgery and therapy. Ann Otol Rhinol Laryngol 1996;105 (6) : 415-22. 11 from the GBI were scaled in standard fashion to range from -100 (maximum negative impact) to 0 (no benefi t) to +100 (maximum benefi t).
Results. Of 25 patients, 12 returned a completed survey (response rate 48%). Th e cohort consisted of 4 (33%) men and 8 (67%) women. Th e mean age was 60.6 years (SD ± 10; range: 42 to 78). Th e average time interval between onset of dystonic symptoms and diagnosis was 14 months (SD ± 20.3; range: 1 to 69 months). Th e average number of physicians seen to make the correct diagnosis was 3. Th e mean duration of treatment was 47 months (SD ± 30.5; range: 5 to 106 months), and the mean interval between BoNT injections was 18 weeks (SD ± 7.2; range: 11 to 35 weeks).
Th e mean total GBI score aft er treatment was 37.7 (SD ± 16.5). Th e means of the GBI subscores were as follows:
• General GBI subscore: 43.1 (SD ± 24.8; p = 0.001); • Social support GBI subscore: 22.2 (SD ± 29.6; p = 0.031); and
• Physical health GBI subscore: 36.7 (SD ± 21.5; p = 0.002).
Following BoNT, the GBI total score and GBI subscores demonstrated improvement. No score was in the negative range, indicating that no patient experienced a negative impact from the injection. Th ere was no association of benefi t as measured by GBI for age, time from onset to diagnosis, length of treatment, or intervals between treatments.
Discussion
OMDs can impair speech, cause physical disfi gurement, and be devastating socially. Of all the OMDs, jaw-opening dystonia has been the most diffi cult to treat. We chose this subset of patients to determine how eff ective BoNT treatments were in improving quality of life.
To assess the eff ectiveness of BoNT on patients' quality of life, we used the GBI, an outcomes research tool developed to measure patient benefi t from otolaryngologic interventions. We modifi ed it to specifi cally address the benefi t of BoNT injections, but the structure of the questions was kept the same. Th e GBI provides a total score and subscores related to general health and well-being, social support, and physical health. As a post-intervention questionnaire, it measures changes in health status produced by an intervention. It is simple for patients to complete and can be applied to patients during therapy.
Our results demonstrated an improvement in quality of life for patients with jaw-opening dystonia receiving BoNT injections. Patients felt more optimistic, less embarrassed, more social, and better about themselves in general as a result of the injections. Th e group of questions regarding social support received the lowest scores of the three groups of questions, indicating that the treatment did not aff ect a patient's social support to a great degree. Specifi c health issues relating to some of the physical disturbances created by the dystonia were also improved by BoNT injections. Although significantly positive, the gains obtained with BoNT injections in physical well-being were not as great as the gains obtained generally and psychosocially.
Th is study had several limitations. First, the patients returning the survey were self-selected and might have represented a skewed population of patients who had signifi cant improvement with BoNT treatments. Th e retrospective nature of the survey also might have affected the results.
As previously stated, although the GBI was created to be given post-intervention, a study comparing pretreatment and post-treatment GBI scores would more likely refl ect the true change in quality of life resulting from the intervention. Also, the open-label design of this study did not include a placebo or control group with which to compare.
Lastly, the small number of patients involved did not allow for broad, conclusive results. However, dystonia is an uncommon disorder, and patients with jaw-opening dystonia represent a small subset of patients with OMD. Th e accumulation of a large database would require a multi-institutional study over a long time period.
In conclusion, BoNT injections were demonstrated to benefi t the quality of life of patients suff ering from jaw-opening OMD. Further investigation and refi nement of this treatment, as well as the development of other treatments, are needed for this devastating disease.
